2017
DOI: 10.1111/bjd.15756
|View full text |Cite
|
Sign up to set email alerts
|

Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

Abstract: The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment paradigms and enabled numerous patients to achieve disease control with an acceptable safety profile. However, the high cost of biologics limits access to these medications for the majority of patients worldwide. In recent years, the introduction of biosimilars for inflammatory diseases has become a fast evolving field. The future use of biosimilars offers the potential for decreased cost and increase… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
35
1
1

Year Published

2018
2018
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(37 citation statements)
references
References 18 publications
0
35
1
1
Order By: Relevance
“…However, as patents for biologics expire, the introduction of biosimilars will contribute to reducing drug costs and improving access to biologics . Biosimilars are biological medicines highly similar in all essential aspects to a reference biological medicine already authorized …”
mentioning
confidence: 99%
See 1 more Smart Citation
“…However, as patents for biologics expire, the introduction of biosimilars will contribute to reducing drug costs and improving access to biologics . Biosimilars are biological medicines highly similar in all essential aspects to a reference biological medicine already authorized …”
mentioning
confidence: 99%
“…6 Biosimilars are biological medicines highly similar in all essential aspects to a reference biological medicine already authorized. [7][8][9][10] Regulatory approval of biosimilars requires evidence that the molecule is similar to the reference product in terms of structure, function, clinical efficacy and safety. [7][8][9]11 MSB11022 (Idacio â ) is a proposed adalimumab biosimilar that has been shown to be structurally and functionally similar to reference adalimumab based on extensive analytical characterization.…”
mentioning
confidence: 99%
“…Genetic backgrounds are also related to the treatment response to biologicals . The high cost of biologicals limits access to these medications; however, cost‐saving biosimilars are rapidly advancing to the market worldwide . Biologicals are effective not only for psoriasis but also for co‐morbid cardiovascular and metabolic diseases .…”
Section: Current Pathogenesis Of Psoriasis and Its Treatmentsmentioning
confidence: 99%
“…87,88 The high cost of biologicals limits access to these medications; however, cost-saving biosimilars are rapidly advancing to the market worldwide. [89][90][91] Biologicals are effective not only for psoriasis but also for co-morbid cardiovascular and metabolic diseases. 92,93 In addition, monitoring of infection is mandatory to avoid serious consequences.…”
Section: Current Pathogenesis Of Psoriasis and Its Treatmentsmentioning
confidence: 99%
“…The article supported by Amgen Inc. published elsewhere in this journal provides a review of what biosimilars are, how they are developed, and what their place in dermatological practice could be. It complements a paper from last year from the International Psoriasis Council (IPC) highlighting the regulatory and market access differences in biosimilars around the world particularly as they relate to psoriasis …”
mentioning
confidence: 98%